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Abstract
Purpose: A study was performed to assess dosimetric characteristics of volumetric modulated arcs (RapidArc, RA)
and fixed field intensity modulated therapy (IMRT) for Whole Abdomen Radiotherapy (WAR) after ovarian cancer.
Methods and Materials: Plans for IMRT and RA were optimised for 5 patients prescribing 25 Gy to the whole
abdomen (PTV_WAR) and 45 Gy to the pelvis and pelvic nodes (PTV_Pelvis) with Simultaneous Integrated Boost
(SIB) technique. Plans were investigated for 6 MV (RA6, IMRT6) and 15 MV (RA15, IMRT15) photons. Objectives were:
for both PTVs V90% > 95%, for PTV_Pelvis: Dmax < 105%; for organs at risk, maximal sparing was required. The MU
and delivery time measured treatment efficiency. Pre-treatment Quality assurance was scored with Gamma
Agreement Index (GAI) with 3% and 3 mm thresholds.
Results: IMRT and RapidArc resulted comparable for target coverage. For PTV_WAR, V90% was 99.8 ± 0.2% and 93.4
± 7.3% for IMRT6 and IMRT15, and 98.4 ± 1.7 and 98.6 ± 0.9% for RA6 and RA15. Target coverage resulted
improved for PTV_Pelvis. Dose homogeneity resulted slightly improved by RA (Uniformity was defined as U5-95% =
D5%-D95%/Dmean). U5-95% for PTV_WAR was 0.34 ± 0.05 and 0.32 ± 0.06 (IMRT6 and IMRT15), 0.30 ± 0.03 and 0.26 ±
0.04 (RA6 and RA15); for PTV_Pelvis, it resulted equal to 0.1 for all techniques. For organs at risk, small differences
were observed between the techniques. MU resulted 3130 ± 221 (IMRT6), 2841 ± 318 (IMRT15), 538 ± 29 (RA6),
635 ± 139 (RA15); the average measured treatment time was 18.0 ± 0.8 and 17.4 ± 2.2 minutes (IMRT6 and
IMRT15) and 4.8 ± 0.2 (RA6 and RA15). GAIIMRT6 = 97.3 ± 2.6%, GAIIMRT15 = 94.4 ± 2.1%, GAIRA6 = 98.7 ± 1.0% and
GAIRA15 = 95.7 ± 3.7%.
Conclusion: RapidArc showed to be a solution to WAR treatments offering good dosimetric features with
significant logistic improvements compared to IMRT.
Introduction
Epithelial Ovarian Cancer (EOC) is a malignancy with
significant probability of trans-peritoneal diffusion for
which, irrespective of multiple surgeries and chemother-
apy applications, a recurrence rate of 60-70% has been
reported [1]. Though not a standard treatment, Whole
Abdomen Radiotherapy (WAR), as adjuvant or as sal-
vage approach has been attempted with limited success
[2,3]. The target volume for WAR includes the whole of
abdominal-pelvic cavity with all its contents. Though
effective in principle, WAR is technically challenging
because of inadequate coverage of large target volume
and poor sparing of organs at risk (OAR) with risk of
severe toxicity [4,5].
The easiest approach to irradiate such a target is to
use simple anterior/posterior beam arrangement with
partial kidney and liver protection [6,7].
The application of advanced techniques like Intensity
Modulated Radiotherapy (IMRT) or Intensity Modulated
Arc Therapy (IMAT) has shown potential to achieve
sufficient uniformity to the target with improved sparing
of OARs [8-10]. WAR with Helical Tomotherapy (HT)
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tion scheme of 30 Gy in 1.5 Gy per fraction to the
entire peritoneal cavity including pelvis and para-aortal
node regions without pelvic boost. Similar approach was
followed by Hong et al [8] and by Duthoy et al [9] (in
the latter case with a prescription of 33 Gy). Garsa et al
[10] applied also a boost up to 44.4 Gy to the pelvis.
Other prescription of radiation doses between 20 and 30
Gy over 20 -25 fractions for WAR and a boost between
40.4 and 51 Gy has been reported [13-15]. This wide
d o s er a n g ei sm o s t l yd u et ot h ea b s e n c eo faw e l l
defined dose response relationship and of an established
consensus till date. However, doses higher than 30 Gy
to whole abdomen and pelvic doses >50 Gy are asso-
ciated with higher incidence of small bowel toxicities
[15] requiring surgery. Moreover, studies which have
shown a substantial benefit in progression free and over-
all survivals have had a component of pelvic boost in
abdominal-pelvic radiation protocols [13,14]. In addi-
tion, although the concept of pelvic boost might be con-
sidered as controversial and its routine usage in
consolidation WAR might be questioned [16], the pelvis
is the major site of relapse and higher doses are toler-
ated by the pelvis [11,17]. It is therefore interesting to
investigate how it can be managed with a Simultaneous
Integrated Boost (SIB) fractionation scheme and inten-
sity modulation. As in Jamema et al [18], in this study a
SIB approach will be investigated for feasibility aiming
to be proposed to patients with complete response after
surgery and chemotherapy or with minimal residual dis-
ease (< 1 cm) as a consolidation therapy.
From the technology point of view, IMAT recently
evolved to the concept of volumetric delivery. RapidArc
(RA), is a method to deliver volumetric intensity-modu-
lated arc therapy based on the original investigations of
Otto [19] and was adopted for this investigation. A
detailed description of the principles of RapidArc can be
found in [20]. RapidArc has been investigated, compared
to IMRT or other approaches, in a series of studies
including brain tumors, prostate, head and neck, anal
canal, cervix uteri and other indications [21-28] showing
some general features summarized in: i) tendency to
improve sparing of organs at risk with respect to con-
ventional, IMRT and sometimes more advanced
approaches; ii) tendency to achieve similar or slightly
improved target coverage with respect to IMRT; iii)
reduced delivery times and lower number of monitor
units per Gy (compared to IMRT).
Purpose of the present work was to further investigate
RapidArc spectrum of possible clinical applications with
a feasibility study. Benchmark for reference was chosen
to be fixed gantry intensity modulation technique,
widely available in most of the clinics. This purpose was
assessed by measuring i) the capability of RapidArc to
generate high quality dose distributions with homoge-
neous doses to WAR target and high sparing of kidneys,
bone marrow and liver; ii) the logistic aspects of treat-
ment efficiency; iii) the degree of agreement of delivered
vs. computed dose distributions. Benchmark used for
this analysis is ‘’conventional’’ fluence-based fixed gantry
IMRT.
Methods and Materials
CT datasets of five patients were used for this study.
Being a planning study aiming to a feasibility demonstra-
tion, data were collected from patients with recurrent
epithelial ovarian cancers of post operative gynecological
cancer, for this reason no clinical details of the patients
are provided. CT Scans were performed with patients in
supine position, arms above head. All patients were asked
to drink 500-1000 ml of water, after having emptied blad-
der, 45 minutes prior to CT scan for constant moderate
bladder filling. CT scans extended from the mid thorax
to mid thighs with 5 mm contiguous slice thickness.
Abdominal Clinical Target Volume (CTV_WAR)
included entire peritoneal cavity with bowel and mesen-
tery, liver capsule with surface of liver parenchyma,
under surface of liver, abdominal surface of diaphragm
and anterior-lateral surfaces of both the kidneys. Pelvic
CTV (CTV_Pelvis) was contoured from L5-S1 vertebral
junction to include pelvic lymph nodal regions, pouch of
Douglas and vaginal vault. Abdominal Planning Target
Volume (PTV_WAR) was drawn with differential mar-
gins to CTV, 1.5 cm cranially (for diaphragm move-
ments) and 0.5 cm in all other directions, similarly pelvic
PTV (PTV_Pelvis) was drawn with 1 cm margin in caudal
d i r e c t i o na n d0 . 5c mm a r g i ni na l lo t h e rd i r e c t i o n s .
Organs at risk (OAR) included: kidneys, liver, bone mar-
row (ribs, vertebrae, pelvic bones and upper end femora),
bladder, rectum and heart. A structure named “normal
liver” was created just inside liver to control doses within
liver parenchyma not included in PTV_WAR (the width
of the outer liver border included in the PTV_WAR ran-
ged from 1 to 1.5 cm). Also for kidneys the same 1-1.5
cm of rim was included in the PTV_WAR, and results
will be reported for the entire kidneys or for the fraction
of kidney outside PTV. This margin was defined to allow
adequate treatment of capsule and rim of OARs parench-
yma with margins for movements. PTV never reached
the surface of the body patients (as can be seen as an
example in figure 1).
Treatment Planning
A total dose of 25 Gy in 25 fractions with 1 Gy per frac-
tion was prescribed to PTV_WAR with simultaneous
boost of 45 Gy in 25 fractions at 1.8 Gy per fraction to
PTV_Pelvis. Plan normalization was set to mean dose to
PTV_Pelvis. Assuming an a/b ratio of 10, the dose
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Equivalent Dose BED of 27.5 Gy (in 25 fractions). This
prescription, lower than what reported in other studies
(e.g. [11,12]) is based on: i) institutional clinical practice,
ii) trade-off against toxicity on major organs at risk, iii)
presence of a simultaneous boost on the pelvis, major
site of recurrences.
Two sets of plans were compared in this study, all
designed by the same planner on the Varian Eclipse
treatment planning system (TPS) (version 8.6) with
photon beams from a Varian Clinac equipped with a
Millennium Multileaf Collimator (MLC) with 120 leaves
(spatial resolution of 5 mm at isocentre for the central
20 cm and of 10 mm in the outer 2 × 10 cm, leaf trans-
mission of 1.8%). Plans for RapidArc were optimised
selecting a maximum DR of 600 MU/min and a fixed
DR of 600 MU/min was selected for IMRT.
The Anisotropic Analytical Algorithm (AAA) photon
dose calculation algorithm was used for all cases [29].
The dose calculation grid was set to 2.5 mm.
The general strategy adopted for both IMRT and
RapidArc was to use two isocentres, aligned in x and y
and separated only in z (cranial-caudal direction of the
patient) of about 15 cm. Rationale for this choice was
the length of the total PTV which ranged from 45 to 51
cm. The upper and lower fields or arc overlap by about
5 cm. The same isocentre settings were used for IMRT
and RapidArc plans. In both cases, all fields or arcs
were simultaneously optimised to generate the desired
dose distributions on all targets.
IMRT
The dynamic sliding window fluence-based method with
fixed gantry beams was used [30,31] as reference bench-
mark. A total of fourteen beams with fixed jaws settings
were applied grouped in two sets of 7 beams per each
isocentre at 0°, 51°, 102°, 153°, 207°, 258°, 309°. Beam
angles were selected in order to avoid opposite entrance.
All beams were coplanar with collimator angle set to 0°.
The first group of beams covered primarily PTV_WAR
and the second group PTV_Pelvis. No bolus was
Figure 1 Isodose distributions in four axial and a coronal views for one example case. Color wash is cut between 5 Gy and 50 Gy. Also
shown the overlay of PTV and main organs at risk.
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optimisation (with the same priority of the highest
priority used for dose volume objectives) to minimise
the MU/Gy from IMRT.
RapidArc (RA)
RapidArc uses continuous variation of the instantaneous
dose rate (DR), MLC leaf positions and gantry rotational
speed to optimise the dose distribution [21,22]. A colli-
mator angle different from 0° is used to smear residual
tongue-and-groove and interleaf leakage effects in non
planar trajectories and, more important, to allow trans-
verse spatial modulation [20] per each degree and per
each axial section of the patient.
Plans were optimised with two arcs of 360° each and a
third arc of 280° excluding the posterior sector (being
RapidArc optimiser in Eclipse 8.6 limited to a total gan-
try rotation of 1000°). The first two arcs, rotating clock-
and counter-clock-wise to minimise dead time between
the two when delivered, were incident primarily on
PTV_WAR and on the upper part of PTV_Pelvis. The
third arc rotating, was incident primarily on PTV_Pelvis
and on the caudal part of PTV_WAR. The overlap
between the two group of arcs was set to ~5 cm. In the
present study the collimator was rotated to ± 30° for the
two arcs irradiating PTV_WAR and to 45° for the arc
covering PTV_Pelvis. The rationale to use two arcs for
P T V _ W A Rw a st h eh u g ev o l u m eo ft h et a r g e tv o l u m e
and the need of high sparing of OARs almost embedded
inside PTVs (liver and kidneys). A multiple arc in this
case is expected to enhance the homogeneity of the
dose and to increase the sparing potential of OARs.
For both techniques, RapidArc and IMRT, two sets of
plans were optimised for each patient using beams of
nominal energy of either 6 MV or 15 MV. At higher
energies it is expected to achieve the better homogeneity
with targets of the sizes involved in this study.
Planning objectives for both PTVs aimed to maximise
coverage with V90% > 95%, for pelvic PTV maximum
dose was constrained to D2% < 47.3 Gy (105% of pre-
scription dose) and V107% <1 %( w h e r eV x% are target
volumes receiving at least x% of the prescribed dose as
Dx% are dose levels delivered at least to x% of volumes).
The constraints to D2% and V107% were not applied to
PTV_WAR since it directly abutted with PTV_Pelvis; in
this case D2% and V107% were to be minimised. In addi-
tion, on targets, dose homogeneity was aimed to be
enhanced as much as possible. For organs at risk, plans
were optimised to obtain the maximum sparing achiev-
able without severe violations of PTV coverage. The
MU and delivery time measured treatment efficiency.
Evaluation Parameters
Evaluation of plans was based on Dose-Volume Histo-
gram (DVH) analysis. For PTV, the values of D98% and
D2% ( d o s er e c e i v e db yt h e9 8 ,a n d2 %o ft h ev o l u m e )
were defined as metrics for minimum and maximum
doses. Also V90% V95% V107% (the volumes receiving at
least 90%, 95%, 107% of the prescribed dose) were
reported. The homogeneity of the dose distribution, was
measured by D5%-D95% and expressed as U5-95% =D 5%-
D95%/Dmean. The lower this value, the better is the dose
homogeneity. Equivalent Uniform Dose (EUD) was com-
puted as well. Conformity Index, CI95%,w a sd e f i n e da s
the ratio between the patient volume receiving at least
95% of the prescribed dose and the volume of the total
PTV_Pelvis, measured the conformity of the high dose
levels. For OARs, the analysis included the mean dose,
the maximum dose expressed as D2% and a set of VXGy
(OAR volume receiving at least x Gy) depending upon
t h eo r g a n .F o rH e a l t h yT i s s u e( d e f i n e da st h ee n t i r e
body volume included in the CT scan minus the PTVs),
the integral dose, “DoseInt” was defined as the integral
of the absorbed dose extended to over all voxels exclud-
ing those within the target volume (DoseInt dimensions
are Gy*cm
3). This was reported together with the
observed mean dose and V10 Gy.
Average cumulative DVH for PTV, OARs and healthy
tissue, were built from the individual DVHs for qualita-
tive visualisation of results. These histograms were
obtained by averaging the corresponding volumes over
the whole patient’s cohort for each dose bin of 0.05 Gy.
Delivery parameters were recorded in terms of MU
per fraction, beam on time and treatment time (defined
as beam-on plus machine programming and setting
time and excluding patient positioning and imaging
procedures).
Pre-treatment quality assurance results were sum-
marised in terms of the Gamma Agreement Index, GAI,
scoring the percentage of modulated area fulfilling the g
index criteria [32] (computed with 2 and 3% and 2 and
3 mm thresholds). The software utilised to analyse dosi-
metric data was Epiqa (Epidos sro, Slovakia) based on
the GLAaS algorithm developed by authors [33,34]. Pre-
treatment dosimetry was considered satisfactory if GAI
exceeded 95%.
The Wilcoxon matched-paired signed-rank test was
used to compare the results. The threshold for statistical
significance was p ≤ 0.05. All statistical tests were two-
sided.
Results
Dose distributions are shown for one patient in Figure 1
for four different axial planes and a coronal view. Col-
our wash banding is restricted to 5-50 Gy. Figure 2
shows the average DVH for the targets and the organs
at risk. Table 1 reports numerical findings from DVH
analysis on PTV_WAR, PTV_Pelvis and Healthy Tissue,
Table 2 on various OARs. Data are presented as
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indicated inter-patient variability at 1 standard deviation
level. Statistical significance is reported when p < 0.05
according to description in the foot notes of the tables.
Additional file 1: Table S1 presents a synoptic com-
parison between this and previous investigations on the
same subject.
Target coverage and dose homogeneity
Data summarised in table 1 show that, for PTV_WAR,
RA plans are very similar although higher energy (15
MV) could be preferable to lower (6 MV) in terms of
lower maximum doses (D2% and V107%)a n db e t t e r
homogeneity (U5-95%). RA15 achieved the best unifor-
mity of dose distributions also in terms of EUD while
showed the largest deviation with about 1 Gy below
(above) prescription for IMRT15 (IMRT6). Concerning
PTV_Pelvis, all four groups resulted to be equivalent.
Organs at risk and healthy tissue
In general, RA15 and IMRT15 resulted in better OARs
sparing compared to RA6 and IMRT6, with a tendency
to significance of observed differences, suggesting a bet-
ter role of higher energy in protecting organs at risk.
IMRT6 resulted in particular defective in sparing kid-
neys (and spinal cord) compared to the other techni-
ques. Also for Healthy Tissue, RA6 and IMRT6 showed
the worst results compared to both RA15 and IMRT15,
suggesting some relevance in using higher energies to
better focalise dose and limiting the dose bath.
The comparison between IMRT15 and RA15, suggests
a basic equivalence between the two techniques
although for bladder-PTV (the portion not included in
the PTVs) and Normal Liver, IMRT has a better sparing
in the dose levels higher than ~20 Gy.
Delivery parameters
The number of MU per fraction of 1.8 Gy resulted 3103 ±
221 (IMRT6), 2841 ± 318 (IMRT15), 538 ± 29 (RA6), 635
± 139 (RA15); this corresponds to the ratios: MUIMRT15/
MURA15 = 4.6 ± 0.9, MUIMRT6/MURA6 =5 . 8±0 . 7 .
The total treatment time from load of patient data
into treatment console to the end of last delivery, was
4.8 ± 0.2 minutes (220 seconds of beam-on) for RA6
Figure 2 Mean dose volume histograms for PTVs and main organs at risk.
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± 0.8 for IMRT15. This difference, besides MU ratio, is
mostly due to the need to re-program the linac between
f i x e dg a n t r yb e a m s ,r o t a t et h eg a n t r yf r o mo n ep o s i t i o n
to the next and to deliver split fields (in average fields
were split because of the size of the target). Time to
move between isocentres is the same for the two
approaches. As mentioned, these values do not include
any imaging or patient positioning procedure, common
to any technique and not relevant for the comparison.
Pre-treatment dosimetric measurements
The Gamma Agreement Index, scored with 3 mm and
3% thresholds was: GAIIMRT6 = 97.3 ± 2.6%, GAIIMRT15
= 94.4 ± 2.1%, GAIRA6 = 98.7 ± 1.0%, GAIRA15 =9 5 . 7±
3.7%. The time (in minutes) needed to perform the pre-
treatment QA is: time for data preparation, including
field by field calculations: 21.0 ± 1.4 for RA and 14.5 ±
2.1 for IMRT; time for measurements was 3.7 ± 0.3 for
RA and 13.4 ± 0.1 for IMRT; time for analysis of data:
1.2 ± 0.1 for RA and 5.1 ± 0.6 for IMRT leading to a
total time for QA procedures of: 25.6 ± 1.5 minutes for
RA with two arcs and 33.0 ± 1.5 minutes for IMRT
with 9 split fields.
Discussion
WAR in Epithelial Ovarian Cancer, though effective, is
used sparingly due to the concerns regarding inadequate
coverage of large target volume, and poor sparing of
organs at risk leading to significantly higher toxicities
[4,5]. Traditionally, conventional radiotherapy techni-
ques using AP/PA fields and 6-15 MV photon beams
with partial OAR shielding is applied but this has major
dosimetric limitations [6,35]. The advent of newer radia-
tion techniques allowed the possibility to treat large
multiple targets with simultaneous integrated boosts
with optimal sparing of critical structures.
Three objectives were set for this study. The first was
the assessment of the RapidArc capability to generate
adequate dose distributions adequate. This result was
achieved and RA plans resulted basically equivalent to
the benchmark IMRT plans. Statistically significant dif-
ferences between IMRT and RA data and between low
and high energy groups have been observed and
reported. Nevertheless, no constant trend was found to
allow to rank one technique or one energy to be abso-
lutely superior to all others for all parameters analyzed.
The second objective was to assess the potential logistic
benefit from the application of RapidArc with respect to
Table 1 Summary of DVH analysis for PTV_A, PTV_Pelvis and healhty tissue
Objective IMRT6 IMRT15 RA15 RA6 p
PTV_WAR (6524 ± 861 cm
3)
Mean [Gy] 25.0 Gy 26.8 ± 0.5 24.8 ± 0.9 25.5 ± 0.5 26.2 ± 0.7 a,c,d
EUD [Gy] - 25.9 ± 0.4 24.0 ± 1.0 25.0 ± 0.3 25.6 ± 0.7 a,c,d
D2% [Gy] Minimise 35.1 ± 1.4 32.9 ± 2.7 31.5 ± 2.2 33.2 ± 2.6 a,b,c,d
U5-95% Minimise 0.34 ± 0.05 0.32 ± 0.06 0.26 ± 0.04 0.30 ± 0.03 a,b,d
D98% [Gy] >22.5 Gy 22.3 ± 0.5 20.7 ± 1.4 21.9 ± 0.4 22.1 ± 0.9 a,c
V90% [%] >95% 99.0 ± 0.6 93.4 ± 7.3 98.6 ± 0.9 98.4 ± 1.7 a,b,c
V95% [%] - 95.6 ± 1.6 89.5 ± 12.0 92.7 ± 2.4 94.1 ± 5.0 a,b,c,d
V107% [%] Minimize 36.3 ± 7.7 13.7 ± 7.7 17.6 ± 8.2 20.1 ± 11.6 a,b,c,d
PTV_Pelvis (1211 ± 158 cm
3)
Mean [Gy] 45.0 Gy 45.0 ± 0.0 45.0 ± 0.0 45.0 ± 0.0 45.0 ± 0.0 -
EUD [Gy] - 44.0 ± 1.6 44.0 ± 1.5 43.9 ± 1.6 44.0V1.9 NS
D2% [Gy] <47.3 Gy 47.6 ± 0.5 47.3 ± 0.4 47.5 ± 0.3 47.5 ± 0.2 NS
U5-95% Minimise 0.1 ± 0.02 0.10 ± 0.01 0.10 ± 0.02 0.10 ± 0.02 NS
D98% [Gy] >40.5 Gy 42.2 ± 0.4 42.1 ± 0.5 41.7 ± 0.5 41.7 ± 0.2 NS
V90% [%] >95% 99.8 ± 0.2 99.7 ± 0.4 99.5 ± 0.3 99.5 ± 0.2 NS
V95% [%] - 95.4 ± 1.9 95.2 ± 2.3 94.0 ± 2.1 94.2 ± 1.1 NS
V107% [%] <2% 0.7 ± 0.9 0.3 ± 0.6 0.5 ± 0.6 0.5 ± 0.6 NS
CI95% minimise 1.60 ± 0.1 1.51 ± 0.1 1.50 ± 0.1 1.50 ± 0.1 NS
Healthy tissue (25772 ± 7089 cm
3)
Mean [Gy] - 19.6 ± 2.1 17.6 ± 1.3 17.6 ± 1.5 18.6 ± 1.6 b,c
V10 Gy [%] - 75.0 ± 6.7 71.1 ± 5.4 70.4 ± 5.1 72.8 ± 5.5 b,c
DoseInt [Gy cm
3 10
6] - 4.94 ± 0.90 4.48 ± 1.00 4.48 ± 0.92 4.74 ± 1.02 b.c
Dx% = dose received by the x% of the volume; Vx% = volume receiving at least x% of the prescribed dose; CI = ratio between the patient volume receiving at
least 95% of the prescribed dose and the volume of the total PTV. U5-95% =D 5-D95/Dmean EUD = Equivalent Uniform Dose. DoseInt = Integral dose, [Gy cm
3 10
6].
Statistical significance (p): a = IMRT15 vs RA15, b = IM6 vs RA6, c = IMRT15 vs IMRT6, d = RA15 vs RA6, NS = Not significative.
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involved, RapidArc proved a clear superiority to IMRT.
In fact, because of the size of the targets, most of the
IMRT fields shall be split due to hardware limitations of
the MLC, as also shown by Hong et al [8], prolonging
delivery time. RA proved to be more efficient also than
HT where delivery time resulted ~2-4 time faster
depending on the study analysed (modulation factors
and field sizes being the key factors for HT). From the
clinical viewpoint, this reflects also into safer treatments
for the patients with reduced risk of internal organs
movement and also patients movement during pro-
longed time on the couch. Most of the studies on whole
abdominal radiotherapy, are based on the need to use at
least two isocentres to cover the cranial-caudal exten-
sion of the target volumes, normally exceeding 40 cm in
length (HT mitigates this issue with the continuous
movement of the couch during irradiation). From IMRT
and RapidArc point of view, the usage of two isocentres
is not detrimental provided that, as in the present study,
the same x and y isocentres coordinates are kept and
only the z (cranial-caudal displacement) is modified. An
overlap region is generated to avoid any field matching.
This allows also an easier quality assurance procedure
with standard IGRT tools (and even 2D planar kV or
MV orthogonal images) where eventual small errors in z
are much easier to be detected. RapidArc plans were
designed using three arcs distributed on two isocentres
performing a simultaneous optimization of all three at
the same time and introducing an overlap of about 5
cm between the superior (one arc) and inferior (two
arcs) groups. The elimination of matching of junction
lines between arcs (also because using different collima-
tor angles the projected lines of the field edges of differ-
ent fields describe different trajectories during the
rotation) implies that PTV and OARs doses in the arc-
overlapping region are accounted for by the optimiza-
tion engine due to the simultaneous processing of all
three arcs preventing undue under- or over-dosages.
T h et h i r do b j e c t i v ew a st oa s s e s st h ed e g r e eo fa g r e e -
ment of delivered vs. computed dose distributions. Rapi-
dArc and IMRT proved a substantial equivalence in
terms of GAI results confirming what already observed
in previous investigations [26,27,33,34].
Some investigations have been performed in the past
years to assess the role of IMRT, IMAT and HT for
WAR. Additional file 1: Table S1 summarizes the main
findings, compared to the present one, from the studies
of Duthoy et al, Hong et al, Garsa et al, Rochet et al,
Jamema et al [8-12,18]. Obviously, similar comparisons
have to be looked with extreme caution since, different
patient selection and more important differences in the
outline of targets and organs at risk can induce major
biases in the relative analysis. The most striking poten-
tial sources of bias are the huge difference in the exten-
sion of the target volumes and in the overlap between
targets and OARs. As an example, in our investigation
1-1.5 cm of rim of kidneys and liver have been included
in the target volume and therefore these volumes had
to be covered by the dose prescribed to PTV.
Table 2 Summary of DVH analysis for organs at risk
IMRT6 IMRT15 RA15 RA6 P
Bone Marrow
(1095 ± 235 cm
3)
Mean [Gy] 24.7 ± 1.4 22.8 ± 1.5 22.6 ± 1.5 23.4 ± 1.3 b,c
D1% [Gy] 44.9 ± 0.9 44.8 ± 0.4 45.5 ± 0.7 45.6 ± 0.9 a,b
V30 Gy [%] 35.0 ± 4.0 31.8 ± 4.1 29.6 ± 5.1 31.5 ± 5.1 b,c
V45 Gy [%] 1.3 ± 1.2 0.9 ± 0.7 2.2 ± 1.3 2.2 ± 1.4 a,b
Bladder (208 ± 219 cm
3)
Mean [Gy] 39.6 ± 1.9 38.7 ± 2.6 39.5 ± 1.5 40.4 ± 1.2 NS
D1% [Gy] 46.9 ± 0.8 48.5 ± 15.2 46.5 ± 0.5 46.9 ± 0.7 NS
V40 Gy [%] 57.8 ± 11.3 58.4 ± 25.8 56.7 ± 9.6 61.4 ± 9.1 NS
Bladder - PTV (131 ±
140 cm
3)
Mean [Gy] 36.5 ± 1.8 35.2 ± 0.8 36.9 ± 0.9 38.3 ± 0.8 a,b,d
D1% [Gy] 45.1 ± 1.3 44.7 ± 1.0 45.3 ± 1.0 46.0 ± 1.6 b
V40 Gy [%] 32.7 ± 12.5 26.1 ± 7.1 31.9 ± 8.6 39.6 ± 8.3 NS
Heart (438 ± 166 cm
3)
Mean [Gy] 9.1 ± 1.6 7.8 ± 1.0 7.7 ± 1.0 8.6 ± 1.1 c,d
D1% [Gy] 23.8 ± 0.5 23.4 ± 0.2 24.2 ± 0.4 24.5 ± 0.4 a,b
Kidneys (242 ± 21 cm
3)
Mean [Gy] 20.0 ± 3.3 14.7 ± 1.8 16.0 ± 1.8 17.0 ± 2.0 a,b,c
D1% [Gy] 31.5 ± 1.5 27.3 ± 1.5 29.7 ± 1.3 29.6 ± 1.5 a,b,c
V20 Gy [%] 51.7 ± 14.7 32.1 ± 8.0 41.1 ± 9.5 42.0 ± 11.0 c
Kidneys - PTV (141 ± 18
cm
3)
Mean [Gy] 16.1 ± 3.0 9.8 ± 1.9 10.3 ± 0.9 11.7 ± 0.7 b,c
D1% [Gy] 25.7 ± 1.9 20.9 ± 1.2 23.2 ± 1.0 23.9 ± 1.5 a,b,c
V20 Gy [%] 22.9 ± 11.9 2.7 ± 28 5.7 ± 2.2 6.9 ± 2.5 a,b,c,d
Liver (1144 ± 231 cm
3)
Mean [Gy] 23.2 ± 0.5 21.8 ± 0.9 22.4 ± 0.7 22.9 ± 0.3 NS
D1% [Gy] 30.9 ± 1.0 29.4 ± 1.4 28.7 ± 0.9 29.6 ± 0.9 NS
V20 Gy [%] 80.7 ± 2.6 77.1 ± 3.5 79.5 ± 3.2 80.5 ± 2.3 c
Normal Liver (273 ± 84
cm
3)
Mean [Gy] 16.4 ± 0.4 14.0 ± 0.9 14.8 ± 0.5 15.9 ± 0.4 b,c
D1% [Gy] 26.5 ± 0.7 25.2 ± 1.3 25.7 ± 0.8 26.6 ± 0.4 c,d
V20 Gy [%] 26.1 ± 3.9 17.2 ± 3.8 23.2 ± 3.1 27.9 ± 2.7 a,c,d
Rectum (129 ± 84 cm
3)
Mean [Gy] 40.7 ± 2.6 40.8 ± 2.4 41.1 ± 2.5 41.3 ± 2.5 NS
D1% [Gy] 46.1 ± 0.9 45.9 ± 0.7 46.4 ± 0.7 46.6 ± 0.5 NS
V45 Gy [%] 9.7 ± 10.9 8.2 ± 4.5 14.9 ± 11.7 17.1 ± 6.1 a,b
Spine (23 ± 6 cm
3)
D1% [Gy] 22.8 ± 1.9 19.0 ± 1.8 19.4 ± 1.1 19.6 ± 1.5 b,c
Dx% = dose received by the x% of the volume; Vx% = volume receiving at
least xGy of the prescribed dose.
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Page 7 of 9This, obviously have a detrimental impact on the dose
reported for these organs which is not easy to account
for data from independent studies where, possibly, dif-
ferent overlaps, if any, are considered. Another source
of discrepancy between studies is the intrinsic definition
of what an OAR is, e.g. the definition of the ‘’bones’’ or
‘’bone marrow’’ structures which directly affects the
values reported (with huge differences appearing
between the Jamema [18] and current study with respect
to, e.g. Rochet or Hong [8,11,12] data.
With a relatively low prescription to PTV_WAR, the
sparing of kidneys and liver, results from Additional file
1: table S1 comparing this study with the results of
other investigations, suggest that RA enables, for this
class of patients, better target coverage (in fact improved
compared to Rochet et al [11,12]) than OAR sparing
(particularly of Rochet et al.). A more neutral compari-
son can be performed between the present study and
the one by Jamema et al [18] which can be better paired
since based on the same volumes and dose prescrip-
tions. From this comparison it results that target cover-
age is slightly superior for HT than for RA but likely
not clinically significant (differently from what observed
from the Rochet et al data where differences are much
more favorable for RA); sparing of liver and bone mar-
row is slightly improved by RA while sparing of kidneys
is equivalent between the two techniques.
A last remark is for respiratory induced motion man-
agement which is not accounted by RapidArc in its pre-
sent form. In whole abdominal treatments, respiratory
motion is strongly correlated with diaphragm motion
which could be subject to tracking given its periodicity.
Feasibility studies were performed and demonstrated the
general potential of tracking for RapidArc [36] but clini-
cal implementation is not yet available. This is different
from what currently available for IMRT where respira-
tory gating is routinely used in several institutes, spe-
cially for breast treatments although abdominal motion
might poorly correlate to chest displacement measured
by Varian’s respiratory gating tools. As a surrogate of
respiratory gating, it was suggested [37] that treatment
during mid-ventilation phase might be reasonable solu-
tion since this is the phase where targets can be “seen”
by static beams for the longest time provided adequate
margins are defined. The dosimetric uncertainties
caused by diaphragm motion were therefore not
accounted for in this study for neither IMRT nor Rapi-
dArc plans but were also not accounted for in most of
the studies with IMRT or Helical Tomotherapy with the
exception of Garsa et al [10].
Conclusion
The study addressed a comparison of RapidArc and IMRT
with fixed gantry for whole abdominal radiotherapy in
patients affected by ovarian cancer. Aims of the study
were met and in summary: i) RapidArc allows the gen-
eration of adequate dose distribution with high target
homogeneity and sufficient sparing of organs at risk,
compared to IMRT; ii) RapidArc offers clear logistic
advantages over IMRT with potential significant clinical
implications, on system throughput and on minimiza-
tion of patient movements; iii) pre-treatment clinical
dosimetry study confirmed high reliability of RapidArc
delivery compared to IMRT and in line with other
recent investigations; iv) treatments at lower energy,
RapidArc of IMRT might be preferable given the similar
dosimetric features of corresponding high energy
approaches because of reduced risk of secondary cancer
induction for long term survivors.
Additional material
Additional file 1: Table S1. Synopsis of some dosimetric findings from
recent investigations on the potential role of IMRT or Tomotherapy or
RapidArc on whole abdomen radiotherapy for ovarian cancer treatment.
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